NUZ-001 Data Shows Multi-Pathway Protein Clearance
Filed with ASX · · 3 pages · English
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Neurizon announces leadership transition
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
- Appendix 4D - Half-year Financial Report - 31 December 2025
- Appendix 4C & Quarterly Update
Later from Neurizon Therapeutics
- Placement of Entitlement Offer Shortfall
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics